GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of dose escalation: what the trials say vs what this community says — 25 comments in the full submission. View in context.
594
c/retatrutide·submitted 1 year ago by u/nikhil_lindqvist

dose escalation: what the trials say vs what this community says

Resultsbranch of 8 comments

Week 94 update. 40kg down from the start, muscle cramps basically gone since about week 51. Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with muscle cramps. The part that surprised me is how much of this is admin.…

Read the full submission and all 25 comments →

This branch

8 comments, started 1 year ago
u/nausea_notesside effects20 points·1 year ago

The glucagon component does different things than dual agonism. The nausea are not just amplified versions.

replysharereportpermalink
u/andres_sorensen15 points·1 year ago

The glucagon component does different things than dual agonism.

Disagree on that part. 98.4% and 98.3% on the same vial is normal.

replysharereportpermalink
u/sena_teixeira11 points·1 year ago

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

replysharereportpermalink
u/elodie_grimaldi6 points·1 year ago

research use only, handling and analysis, not protocols

replysharereportpermalink
u/bilal_osei3 points·1 year ago

I am going to push back on this slightly.

replysharereportpermalink
u/lurker_for_years4 points·1 year ago

triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual

replysharereportpermalink
u/matias_falk16 points·1 year ago

the dosing is steep, the reflux reports are real, and nobody knows the human safety yet

replysharereportpermalink
u/sofia_wikstrom10 points·1 year ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/retatrutide
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/reta_and_regretu/trialwatch_theou/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →